Vertex Pharmaceuticals

Market Cap (Mar-08-2026)

116.015 Billion USD

World Rank (Jan-05-2024)

129

Market Cap (Jan-05-2024)

107.235 Billion USD

World Rank (Jul-30-2023)

161

Market Cap (Jul-30-2023)

91.186 Billion USD

World Rank (Jan-07-2022)

323

Market Cap (Jan-07-2022)

56.406 Billion USD

World Rank (Jan-01-2021)

249

Market Cap (Jan-01-2021)

61.457 Billion USD

Company Rank in Country in 2023

Rank in USA in July-2023 is 92

Headquarters Country

USA

Nasdaq / NYSE Code

VRTX

CEO

Reshma Kewalramani

Founders

Joshua Boger

Employee Count

4,500

Employee Count as of Date

As on 2022

Headquarters City/State

Massachusetts

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

12,001 Million USD

Annual Operating Income in USD

4,173 Million USD

Annual Net Income in USD

3,953 Million USD

Annual Results for Period Ending

Dec-2025 ending year

Total Assets in USD

25,643 Million USD

Total Liabilities in USD

6,977 Million USD

Total Equity in USD

18,666 Million USD

Balance Sheet for Period Ending

Dec-2025 ending year

Business Sector

Company Website

Vertex Pharmaceuticals

Wikipedia

Yahoo

Yahoo @ Nasdaq

Company Profile

VERTEX PHARMACEUTICALS is USA Based Bio-Technology, Bio-Pharmaceutical and Healthcare Company.It have research and development sites, manufacturing facilities and offices around the world. The company locations are North America, Europe, Australia, South America.

As on 2022, VERTEX PHARMACEUTICALS has 4,500 employees.

VERTEX PHARMACEUTICALS annual revenue generated for period ending Dec-2022 was 8,930 million USD.

VERTEX PHARMACEUTICALS annual net income generated for period ending Dec-2022 was 3,322 million USD.

VERTEX PHARMACEUTICALS annual revenue generated for period ending Dec-2021 was 7,574 million USD.

Split of Annual Revenue by business segment for period ending Dec-2021:

TRIKAFTA/KAFTRIO: 5,697 million USD.
SYMDEKO/SYMKEVI: 420 million USD.
ORKAMBI: 771 million USD.
KALYDECO: 684 million USD.
Other Revenue: 1 million USD.

VERTEX PHARMACEUTICALS annual net income generated for period ending Dec-2021 was 2,342 million USD.

Total Assets as on Dec-2021 was 13,432 Million USD.

Total Liabilities as on Dec-2021 was 3,332 Million USD.

Total Equity as on Dec-2021 was 10,100 Million USD.

Annual Results Summary

VERTEX PHARMACEUTICALS - Annual Results - Revenue and Net Income - in Million USD:

Year - Ending	Revenue	Operating Income	Net Income
Dec-2023	9,869	4,307	3,619
Dec-2022	8,930	4,365	3,322
Dec-2021	7,574	2,782	2,342
Dec-2020	6,205	2,869	2,711
Dec-2019	4,163	1,202	1,177
Dec-2018	3,047	664	2,097
Dec-2017	2,488	392	263
Dec-2016	1,702		-112

Balance Sheet Summary

VERTEX PHARMACEUTICALS - Balance Sheet Summary - in Million USD:

Year Ending:	Total Assets	Total Liabilities	Total Equity
Dec-2023	22,730	5,149	17,580
Dec-2022	18,150	4,238	13,912
Dec-2021	13,432	3,332	10,100
Dec-2020	11,752	3,065	8,687
Dec-2019	8,318	2,233	6,085
Dec-2018	6,246	1,811	4,435
Dec-2017	3,546	1,517	2,029

Founded Year

1989

Institutional Investors

Top 30 Institutional Holder Names in VERTEX PHARMACEUTICALS as on SEP-30-2023

RANK	INSTITUTION NAME	DATE	SHARES HELD	CHANGE (SHARES)	CHANGE (%)	VALUE (IN 1,000S)
1	BLACKROCK INC.	09/30/2023	2,25,85,226	-2,35,200	-1.03%	$7,889,923
2	VANGUARD GROUP INC	09/30/2023	2,19,83,356	87,397	0.40%	$7,679,666
3	CAPITAL WORLD INVESTORS	09/30/2023	1,79,81,667	6,41,033	3.70%	$6,281,716
4	FMR LLC	09/30/2023	1,43,60,437	-2,68,229	-1.83%	$5,016,675
5	STATE STREET CORP	09/30/2023	1,20,39,546	-2,92,047	-2.37%	$4,205,895
6	ALLIANCEBERNSTEIN L.P.	09/30/2023	75,26,456	-8,578	-0.11%	$2,629,292
7	PRICE T ROWE ASSOCIATES INC /MD/	09/30/2023	68,50,066	91,308	1.35%	$2,393,002
8	WELLINGTON MANAGEMENT GROUP LLP	09/30/2023	65,25,851	-10,27,043	-13.60%	$2,279,741
9	JPMORGAN CHASE & CO	09/30/2023	61,05,852	1,50,327	2.52%	$2,133,018
10	GEODE CAPITAL MANAGEMENT, LLC	09/30/2023	55,95,974	51,113	0.92%	$1,954,898
11	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	09/30/2023	38,91,794	-49,327	-1.25%	$1,359,559
12	JENNISON ASSOCIATES LLC	09/30/2023	37,97,665	-7,976	-0.21%	$1,326,676
13	CAPITAL RESEARCH GLOBAL INVESTORS	09/30/2023	33,72,584	3,10,908	10.16%	$1,178,178
14	LOOMIS SAYLES & CO L P	09/30/2023	31,63,468	-1,11,842	-3.42%	$1,105,126
15	CLEARBRIDGE INVESTMENTS, LLC	09/30/2023	29,43,184	-2,08,238	-6.61%	$1,028,172
16	AMERIPRISE FINANCIAL INC	09/30/2023	29,37,812	-86,031	-2.85%	$1,026,295
17	MORGAN STANLEY	09/30/2023	28,70,101	89,217	3.21%	$1,002,641
18	NORTHERN TRUST CORP	09/30/2023	28,13,563	1,31,539	4.90%	$982,890
19	UBS ASSET MANAGEMENT AMERICAS INC	09/30/2023	27,73,799	-37,932	-1.35%	$968,999
20	NORGES BANK	12/31/2022	24,51,521	1,63,049	7.13%	$856,414
21	BANK OF AMERICA CORP /DE/	09/30/2023	23,53,001	12,926	0.55%	$821,997
22	LEGAL & GENERAL GROUP PLC	09/30/2023	20,40,358	-88,561	-4.16%	$712,779
23	INVESCO LTD.	09/30/2023	20,16,780	67,451	3.46%	$704,542
24	BANK OF NEW YORK MELLON CORP	09/30/2023	20,13,896	16,439	0.82%	$703,534
25	AMUNDI	09/30/2023	19,43,421	2,97,580	18.08%	$678,915
26	GOLDMAN SACHS GROUP INC	09/30/2023	16,95,325	-1,20,547	-6.64%	$592,245
27	RENAISSANCE TECHNOLOGIES LLC	09/30/2023	16,64,088	3,91,927	30.81%	$581,333
28	JANUS HENDERSON GROUP PLC	09/30/2023	16,58,823	2,23,905	15.60%	$579,493
29	CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	09/30/2023	15,09,961	42,343	2.89%	$527,490
30	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	09/30/2023	14,67,428	17,564	1.21%	$512,631